Muscle-Invasive Bladder Carcinoma Clinical Trial
Official title:
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients With MIBC (RAD-SG).
The purpose of this study is to examine the safety and tolerability of treatment with concurrent Sacituzumab Govitecan (SG) and adaptive radiation therapy. The main objective is to establish the safety, tolerability, and feasibility of bladder preservation therapy treatment with concurrent SG and adaptive image-guided radiation therapy for participants with localized MIBC. Participants will receive the study drug, SG, through an IV once weekly on days 1 and 8 of each 21-day treatment cycle. The first cycle of SG will begin 21 days prior to the scheduled start of radiation therapy. The second and third cycles of SG will be given while the participant is receiving radiation therapy. Participants will be asked to undergo computed tomography (CT) and magnetic resonance imaging (MRI) pre-and post-treatment. Participation in the research will last up to 5 years, depending on treatment outcomes, with a treatment period of 8 weeks and a study follow-up period of up to 2-5 years thereafter, and a survival follow-up, with only phone call communication from years 3-5.
Treatment patterns in the community demonstrate that a substantial proportion of participants with bladder cancer do not receive curative intent therapy, especially if unfit for or refuse radical cystectomy. Concurrent chemoradiation is an accepted alternative to radical cystectomy, however systemic radio sensitizing chemotherapy may have significant off target side effects. This study is investigating the concurrent administration of a bladder cancer targeted antibody drug conjugate with radiotherapy. Sacituzumab govitecan (SG), or IMMU-132 is an investigational new drug that utilizes an antibody-drug conjugate (ADC) to target and kill epithelial bladder cancer cells. SG is experimental because it is not approved by the Food and Drug Administration (FDA) for use in this setting. The aim for this study is to establish the safety, tolerability, and feasibility of bladder preservation therapy treatment with concurrent SG and adaptive image-guided radiation therapy for platinum ineligible participants with localized MIBC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05097404 -
Clinical Utility of VI-RADS in Diagnosis of MIBC
|
||
| Recruiting |
NCT05483868 -
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04966130 -
Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
|
||
| Active, not recruiting |
NCT04610671 -
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
|
Phase 1 | |
| Recruiting |
NCT06341400 -
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06190197 -
Prophylactic Antibiotics in Cystectomy With Diversion
|
Early Phase 1 | |
| Recruiting |
NCT05203913 -
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT05790850 -
Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
|
N/A | |
| Recruiting |
NCT05295992 -
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
|
N/A | |
| Recruiting |
NCT06215976 -
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
|
Phase 4 | |
| Recruiting |
NCT05028660 -
AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
|
||
| Not yet recruiting |
NCT06417190 -
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
|
Phase 2 | |
| Not yet recruiting |
NCT04909775 -
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04876313 -
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
|
Phase 2 | |
| Not yet recruiting |
NCT04686149 -
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
|
||
| Active, not recruiting |
NCT05630131 -
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
|
||
| Recruiting |
NCT06170177 -
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
|
||
| Terminated |
NCT05221827 -
Clinical Performance Evaluation of the C2i-Test
|
||
| Recruiting |
NCT06257017 -
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial
|
Phase 2 | |
| Recruiting |
NCT05767528 -
Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection
|